CryoPort (CYRX) agreed to provide its IntegriCell cryopreservation services to support Verismo Therapeutics' KIR-CAR T-cell therapy programs for two product candidates, the companies said Thursday.
No financial terms were disclosed.
Verismo will use IntegriCell to support cryopreservation of the development of SynKIR-110 as a potential treatment for solid tumors and SynKIR-310 in B-cell associated disorders and malignancies, according to the company.
Both product candidates are currently under phase 1 human clinical trials, the companies said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments